US Patent

US12201615 — Methods and compositions for treatment of mydriasis

Method of Use · Assigned to Opus Genetics Inc · Expires 2039-12-25 · 14y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods and compositions for treating mydriasis and other ocular disorders using an alpha-adrenergic antagonist like phentolamine.

USPTO Abstract

The invention provides methods, compositions, and kits containing an alpha-adrenergic antagonist, such as phentolamine, for use in monotherapy or as part of a combination therapy to treat patients suffering from presbyopia, mydriasis, and/or other ocular disorders.

Drugs covered by this patent

phentolamine-mesylate (PHENTOLAMINE MESYLATE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3804`	—	phentolamine-mesylate

Patent Metadata

Patent number: US12201615
Jurisdiction: US
Classification: Method of Use
Expires: 2039-12-25
Drug substance claim: No
Drug product claim: No
Assignee: Opus Genetics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.